Tuhura Biosciences, Inc. (HURA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 22, 2026, covering events occurring on April 21, 2026. Tuhura Biosciences, Inc., a clinical-stage biopharmaceutical company, entered into a material definitive agreement to secure funding for its ongoing clinical trials and development programs, specifically for its IFx-20 product candidate.
Key Financial Metrics and Capital Structure
- Debt Facility: Entered into a $50 million revolving credit facility with Parkview Holdings One LLC (an affiliate of the Company's largest stockholder).
- Interest Rate: 12% per annum, increasing to 18% (12% + 6%) upon an event of default.
- Maturity Date: April 21, 2031.
- Collateral: Secured by substantially all assets of the Company and its subsidiaries.
- Commitment Fee: $5.0 million (10% of total commitment), payable via the issuance of 1,878,287 shares of common stock (subject to shareholder approval) or cash if approval is not received by September 1, 2026.
- Annual Facility Fee: 1.5% of the total commitment, payable in cash annually.
- Drawdown Limits: Up to one draw per month, capped at the greater of $1.7 million or the monthly budgeted expense amount.
- Repayment Trigger: If the Company achieves net profits from pharmaceutical sales for two consecutive fiscal quarters, it must repay 75% of such net profits from the previous quarter.
- Royalty Obligation: Granted Parkview an annual royalty on Net Sales of products based on IFx-2.0 intellectual property (low to mid-single digits percentage) up to $450 million in annual Net Sales.
Material Changes and Related Agreements
The filing details the execution of a Loan Agreement, a Royalty Agreement, a Fee Letter, and two Warrant Amendment Agreements. Key changes include:
- Warrant Extension: Extended the exercise period for 4,364,873 warrants held by K&V Investment One LLC (affiliate of Parkview) to April 21, 2031. These warrants have exercise prices of $3.69 and $5.70.
- Board Representation: Parkview has the right to appoint a director to the Company's board upon request.
- Change of Control Conversion: In the event of a Change of Control (acquisition of 51%+ equity by a third party), Parkview may convert outstanding principal and accrued interest into common stock at a conversion price of $2.662 per share, subject to shareholder approval.
- Covenants: The agreement imposes restrictions on additional debt, investments, dispositions, and amendments to organizational documents.
Outlook, Risks, and Management Commentary
Management expects the credit facility to provide sufficient capital to fund operations and development programs into the first quarter of 2028, assuming shareholder approval of the Loan Fee Shares. The filing highlights several risks:
- Liquidity Risk: Funds available may be insufficient to meet anticipated operational needs.
- Compliance Risk: Failure to satisfy drawdown conditions or maintain covenant compliance could trigger an event of default.
- Related Party Risk: Potential conflicts of interest arising from the transaction with an affiliate of the largest stockholder.
- Default Triggers: Events of default include a Change of Control or the discontinuance of the IFx-20 development program.
Investor Verification Checklist
- Verify the status of shareholder approval for the issuance of 1,878,287 Loan Fee Shares by the August 31, 2026 deadline.
- Review the specific terms of the "monthly budgeted expense amount" to understand the practical drawdown limits.
- Assess the impact of the 12% interest rate and 1.5% annual fee on the Company's future cash burn rate.
- Confirm the current valuation of the Company's assets pledged as collateral against the $50 million facility.
- Monitor the progress of the IFx-20 development program, as its discontinuance constitutes an immediate event of default.